We are proud to announce that Biocytogen will attend ADA 2026 Scientific Sessions, the largest conference in the world focused on diabetes. Come meet our experts at booth #1300 to learn about our humanized mouse models targeting sugar and lipid metabolism and how they’re supporting breakthroughs in metabolic disease research.
What is ADA?
The American Diabetes Association (ADA) is the largest conference in the world focused on diabetes, with this year’s meeting bringing together over 12,000 researchers and clinicians. These professionals unite to discuss innovative solutions and build purposeful partnerships, improving the future of patient outcomes.
Event Overview
Date: June 5th - 8th, 2026
Venue: Ernest N. Morial Convention Center, 900 Convention Center Blvd, New Orleans, LA 70130
Event Schedule
For more information, please refer to the event schedule.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s drive the future of diabetes research and care together, we look forward to meeting you in New Orleans, LA!
